Home/Pipeline/Schizophrenia

Schizophrenia

Pre-clinicalActive

Key Facts

Indication

Schizophrenia

Phase

Pre-clinical

Status

Active

Company

Keltic Pharma Therapeutics

About Keltic Pharma Therapeutics

Keltic Pharma Therapeutics is a private, preclinical-stage biotech company developing a proprietary drug discovery platform called PEPSMOL©. This platform aims to create 'synthetic biologics' to target hard-to-drug GPCRs, with initial in-house programs targeting severe asthma, malaria, Alzheimer's disease, and schizophrenia. The company, founded by three renowned University of Glasgow professors, is pre-revenue and has secured non-dilutive grant funding, including a SMART Grant from Innovate UK in 2024, to advance its platform and pipeline.

View full company profile

Therapeutic Areas

Inflammatory Diseases Infectious Diseases Neurology Psychiatry

Other Schizophrenia Drugs

Drug	Company	Phase	Status
DB103 (Pomaglumetad)	Denovo Biopharma	Phase 2b/3	Active
ZZ6398	Zhongze Therapeutics	Phase 1/2	Active
RBP-7000 (PERSERIS®)	Indivior	Marketed	Commercial
Undisclosed Programs	johnson-and-johnson-innovative-medicine	Pipeline	Active
Schizophrenia Candidate	Teva	Phase 3	Active
Schizophrenia Model Service	NeuroProof	Pre-clinical	Active
LYN-005 (Nortiva)	Lyndra	Phase 3	Active
TerXT	Terran Biosciences	Late-stage (Pre-Phase 3)	Active
Undisclosed Program	Curemark	Preclinical	Active
Schizophrenia Intermediate	OFD Biopharma	Proof of concept	Active
AVAT-031	Avata Biosciences	Discovery	Active
Risperidone Implant	Delpor	Phase 1b/2a / Late-stage	Active